|Mr. Evan Karras||CEO, Pres, Sec. & Director||N/A||N/A||N/A|
|Mr. Nunzio J. Valerie Jr.||CFO & Director||N/A||N/A||1962|
|Mr. Vince Demasi||COO & Director||N/A||N/A||N/A|
|Dr. Lilla Albert Ph.D.||Chief Marketing and Technology Officer||N/A||N/A||N/A|
|Ms. Elena Milantoni||Director of Fin. and Admin.||N/A||N/A||1970|
Easton Pharmaceuticals Inc., a specialty pharmaceutical company, develops and markets various topically delivered drugs to treat cancer and other therapeutic products to treat various conditions. Its products include Nauseasol, a motion sickness gel; Skin Renou HA, an anti-aging wrinkle cream using hyaluronic acid, which keeps the skin smooth; Kenestrin Gel used for arthritis, knees, elbows, shoulders, wrist, and back pain; and Viorra, a hormone free, non-toxic, and topical gel that improves sexual functioning of women. The company was formerly known as LAM Industries, Inc. and changed its name to Easton Pharmaceuticals Inc. in March 2010. Easton Pharmaceuticals Inc. was founded in 1997 and is headquartered in Toronto, Canada.
Easton Pharmaceuticals Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 5.